Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1 by Jaeger, E. et al.
Nature GeNetics  VOLUME 44 | NUMBER 6 | JUNE 2012 699




















Colorectal cancers that arise as a result of high-penetrance germline 
mutations in genes such as APC, MSH2 and MLH1 are associated 
with tumors of particular morphology and with variable but specific 
extra-colonic features. HMPS is an unusual disease, in that affected 
individuals can develop polyps of multiple and mixed morphologies— 
including serrated lesions, Peutz-Jeghers polyps, juvenile polyps, con-
ventional adenomas and colorectal carcinoma (CRC)1—in the absence 
of any identifiable extra-colonic features. A single large Jewish family 
with HMPS (SM96) with dominantly inherited polyposis was initially 
identified at St Mark’s Hospital, London, and germline mutations in 
known CRC predisposition genes were excluded over time2. Using 
linkage analysis in SM96 and independently in another Jewish kindred 
with polyposis, SM1311, we mapped the causative gene to CRAC1 
(also known as HMPS) on chromosome 15q13.3 and showed that the 
two families shared a haplotype within this region2,3. Subsequently, 
we identified additional kindreds with HMPS on the basis of their 
clinical features and Ashkenazi descent and showed that all fami-
lies shared a disease haplotype between 30.735 Mb and 31.370 Mb 
on chromosome 15q13.3 (ref. 4). To date, no non-Ashkenazi fami-
lies with HMPS have convincingly been identified, although there 
is overlap between some of the clinical features of HMPS and those 
of juvenile polyposis syndrome (JPS)5 and hyperplastic polyposis 
syndrome (HPPS)6.
The possibility that a large proportion of HMPS cases was caused 
by a single founder mutation led us to hypothesize that the underlying 
genetic change might be somewhat unusual: we reasoned that 
disease-causing mutations might be of a very specific type that 
occurred infrequently as spontaneous events. Consistent with this 
notion, we found no convincing evidence of loss of heterozygosity at 
15q13.3 in 12 tumors from individuals with HMPS (data not shown), 
suggesting that the gene was not a classical tumor suppressor. We also 
sequenced three subjects with HMPS and two unaffected relatives 
who did not share the disease haplotype for the coding regions of 
the three genes (GREM1, SCG5 and FMN1) that lie within the region 
of the shared haplotype. We found known polymorphisms but no 
novel, potentially pathogenic changes that were consistently present 
in affected subjects and absent in their unaffected relatives.
We therefore wondered whether the underlying mutation in 
HMPS might take the form of a copy-number change. We designed 
a custom oligonucleotide array to search for copy-number variation 
in the region. This analysis showed the presence of a heterozygous 
single-copy duplication of approximately 40 kb centered on chr. 15: 
30.77 Mb in two subjects with HMPS and in none of their three unaf-
fected relatives (Fig. 1 and Supplementary Fig. 1). PCR amplification 
across the duplication breakpoints subsequently mapped it to chr. 15: 
30,752,231–30,792,051. The change was found to be a simple tandem 
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tail-head duplication with the insertion of a 
30-bp sequence of unknown origin and no 
homology to known sequences between the 
duplicons. The duplication extended from 
intron 2 of SCG5 to a site just upstream of the 
GREM1 CpG island (Fig. 1). In order to inves-
tigate the duplication further, we designed 
PCR primers that spanned the duplication 
boundary and produced a unique, specific 
amplification product of 190 bp. As a control, 
we chose a region upstream of GREM1 that 
was present in all individuals, which gener-
ated a product of 435 bp. We tested 40 affected 
individuals (Supplementary Fig. 2) and 
50 unaffected individuals (either polyp-free 
but at-risk persons who were >40 years old 
or the spouses of affected individuals) from 
6 putative families with HMPS. There was perfect concord-
ance between presence of the 190-bp product and affected status 
(Supplementary Fig. 1 and Supplementary Table 1). We then 
tested 188 unselected Ashkenazi controls, and none showed ampli-
fication of the 190-bp product; this group included one duplication- 
negative individual who shared the HMPS haplotype, suggesting that 
the duplication had arisen on that haplotype background.
We then wondered whether duplication of chromosome 15q13.3—
either identical to that in HMPS or a similar change—might be present 
in a set of familial CRC cases from the general population of the UK. 
We therefore used the QuantiSNP program7 to analyze our existing 
Illumina Hap550 SNP array data from 718 CRC cases and 935 controls 
enrolled in the Colorectal Tumour Gene Identification (CORGI) study 
of CRC genetics8. One case, but no control, was found to have a dupli-
cation close to GREM1 and SCG5, and we showed that this change 
was identical to that found in the HMPS cases. The subject concerned 
had been excluded from the CORGI genome-wide association study 
because ancestry was uncertain in principal-component analysis. On 
further investigation, we found that the family of this individual was 
of Ashkenazi descent and had a phenotype of multiple polyps and 
CRC, entirely compatible with HMPS but not previously diagnosed as 
such (Supplementary Fig. 2). We found no non-Ashkenazi affected 
individuals with duplications in the region implicated in HMPS.
Although the SCG5-GREM1 duplication was highly likely to be 
pathogenic and was an unusual type of mutation consistent with the 
seeming monophyletic origin of HMPS, we wished to exclude the pres-
ence of other potentially pathogenic variants on the HMPS haplotype. 
We therefore screened the entire ancestral haplotype region (chr. 15: 
30,735,098–31,369,755) in 2 cases and 3 unaffected individuals 
from 3 different families with HMPS through sequencing of 454 
amplicons. In addition, we sequenced the region in two somatic 
cell hybrids that had been generated, one of which carried a copy 
of the mutant chromosome 15 and the other of which had a copy of 
the wild-type chromosome from an individual with HMPS. After 
 filtering out variants that were present in dbSNP and a small number 
of artifacts, only three variants were specifically present in all cases 
and in no controls. All three variants were single-nucleotide changes 
deep within introns of FMN1 (Supplementary Table 2). None of the 
changes was predicted to have profound functional effects, although 
one change at a conserved location at the beginning of FMN1 (base 
31,038,855) lay within a DNase I hypersensitive site, thus having the 
potential to affect gene transcription. Differences in FMN1 transcrip-
tion were subsequently excluded as a possible mechanism.
Given that the SCG5-GREM1 duplication was by far the most likely 
pathogenic mutation in the HMPS region, we sought to determine 
which gene(s) was affected by this change. Because the duplication 
involved the latter half of the coding region of SCG5 in addition to 
a large part of the region between SCG5 and GREM1, we initially 
attempted to detect aberrant SCG5 transcripts in the affected individu-
als on the basis of predictions from the duplicated exons. However, only 
the normal SCG5 mRNA species was found (data not shown). We then 
wondered whether the duplication could act as an enhancer of gene 
transcription. mRNA levels of SCG5, GREM1 and FMN1 were assayed 
in 87 individual normal colonic crypts from 8 subjects with HMPS and 
in 55 individual crypts from 8 UK controls, as well as in 8 crypts from 
1 family member with HMPS who did not have the duplication. The 
control subjects had clear colonoscopies and no history of colorectal 
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Figure 1 The HMPS duplication. (a) Array 
comparative genomic hybridization (CGH) 
analysis of the region around the HMPS 
duplication. The region of copy-number gain, 
estimated to be at a 3:2 ratio relative to controls 
and, hence, resulting from a single-copy gain,  
is indicated. Results from the full region 
analyzed are shown (supplementary Fig. 1).  
(b) Schematic of the 40-kb duplication 
showing the involvement of the 3′ half of SCG5 
extending to a region upstream of GREM1.
The locations on chromosome 15 of coding 
sequences, introns, selected SNPs and CpG 
islands are shown for wild-type and mutated 
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normal epithelium of subjects with HMPS compared to the controls, 
but no significant differences in the expression of SCG5 or FMN1 were 
detected (Fig. 2). Allele-specific expression (ASE) analysis showed sig-
nificantly increased expression of the duplicated allele in HMPS crypts 
(Mann-Whitney P = 0.0009). Attempts to confirm that the duplicated 
allele was expressed more strongly in lymphoblastoid cells from the 
subjects with HMPS were unsuccessful because we found GREM1  
levels to be very low in these cells. We did, however, examine expres-
sion in the somatic cell hybrids carrying the mutant or wild-type copy 
of chromosome 15, as these cells were derived from mouse fibroblast 
lines that expressed GREM1. We detected 4.6-fold higher GREM1 
mRNA expression in the cells with the mutant copy of human chro-
mosome 15 compared to those carrying the wild-type copy.
We then examined the localization of GREM1 mRNA in the normal 
colorectal crypts of subjects with HMPS and controls. In controls and 
family members with HMPS without the duplication, GREM1 mRNA 
was restricted to intestinal subepithelial myofibroblasts (ISEMFs) at 
the crypt base, as has previously been reported9,10. In subjects with 
HMPS, by contrast, GREM1 was expressed, not only in basal ISEMFs, 
but also at very high levels in epithelial cells (predominantly colono-
cytes), with expression extending most of the way up the sides of the 
crypt (Fig. 2). Increased GREM1 expression was also seen in HMPS 
polyps, albeit to a lesser extent than in normal epithelium.
Given the increased and ectopic expression of GREM1 in indi-
viduals with HMPS, we tested whether elements within the HMPS 
duplication could enhance gene transcription. Although data from 
the Encyclopedia of DNA Elements (ENCODE) suggest that at 
least two regions within the duplication might have enhancer activ-
ity (Supplementary Fig. 3), we focused on a 3-kb region (chr. 15: 
30,779,000–30,782,000) because we had previously shown this to 
have histone H4 lysine 4 (H4K4) acetylation and histone H3 lysine 4 
(H3K4) methylation marks indicative of active chromatin11, and we 
subsequently showed by chromatin immunoprecipitation that this 
region contained transcription factor–binding sites (M.B., A.L. and 
I.T., unpublished data). Using a luciferase reporter assay, we found that 
a fragment encompassing this 3-kb region was capable of enhancing 
gene expression by fourfold in the SW948 CRC cell line that expresses 
GREM1 (P = 0.00002, t test; Supplementary Table 3). We then used 
chromatin conformation capture (3C) to show that the 3-kb region 
interacts directly with the GREM1 promoter in GREM1-expressing 
CRC cell lines (data not shown). Using 3C analysis in the chromosome 
15 somatic cell hybrids, we showed much stronger promoter interac-
tion in the hybrid with the duplication than in the control (Fig. 3).
The BMP signaling pathway is not well characterized compared to 
other pathways. The canonical pathway signals through BMP receptors 
and drives expression of the ID transcriptional repressor genes 
through the activities of SMAD1, SMAD5 and SMAD8 (SMAD1/5/8). 
A non-canonical pathway acts through decreased PTEN expression 
and increased levels of active Akt12. BMP2 and BMP4, the primary 
ligands in the colorectum, have been postulated to act against the 
stem cell phenotype, and, hence, increased GREM1 levels would 
be expected to reduce BMP ligand levels and promote the stem cell 
phenotype. In keeping with this hypothesis, we found a small but 
significant increase in the expression of the stem and/or progenitor 
cell marker LGR5 in whole HMPS colonic crypts compared to crypts 
from controls (P = 0.03, Mann-Whitney test). There was no detectable 

































Figure 2 Expression of GREM1, SCG5 and FMN1. (a) Expression levels 
of each mRNA by quantitative RT-PCR (qRT-PCR) analysis of multiple 
individual crypts of normal morphology from subjects with HMPS relative to 
controls. Error bars, s.d. Note the greatly increased expression of GREM1. 
Immunohistochemistry provided no evidence of differences in SCG5 
expression in subjects with HMPS and controls (data not shown); reliable 
antibodies are not available for GREM1 and FMN1. (b) Representative light- 
(left) and dark-field (right) mRNA ISH of GREM1 mRNA in colorectum of 
normal appearance from a control (unaffected) individual compared with an 
individual with HMPS. GREM1 is restricted to ISEMFs and the subcryptal 
smooth muscle layer (indicated by arrows) in the control individual but is 
found throughout the crypt epithelium in the individual with HMPS.
0
30,760,000









































6 Figure 3 3C analysis of a region upstream of GREM1 in somatic cell hybrids 
carrying a wild-type chromosome 15 or a copy with the HMPS duplication.  
The genomic region of GREM1 is depicted below the x axis, with the  
telomeric limit of the duplication shown in gray and exons shown in blue.  
The 3-kb region within the duplication on which we focused is indicated by  
an orange bar. The 3C constant region and its primer and probe sites (red)  
are located on a BglII fragment containing the transcription start site and  
exon 1 of GREM1. Assayed BglII restriction fragments are shown as vertical  
gray lines. Variable human-specific primers (green) are located at the 3′ end 
of selected fragments. The relative cross-linking frequencies of each 
upstream fragment derived from qRT-PCR were normalized to a BAC control 
and calculated as the ratio of individual site cross-linking frequencies to the 
cross-linking frequency of the first upstream adjacent BglII fragment (Up1). 
The H13 hybrid cell line with the HMPS duplication showed a specific 
increase in the interaction of the 3-kb region with the GREM1 promoter. 
The H12 cell line, containing the wild-type human allele, also showed some 
interaction between these sequences compared with the corresponding 
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subjects with HMPS, and we were not able to show an increase in 
ID1, ID2 and ID3 (ID1/2/3) expression in crypts from subjects with 
HMPS relative to controls. We did, however, detect decreased PTEN 
expression in some polyps from subjects with HMPS (but not in tissue 
of normal appearance), together with patches of complete PTEN 
loss (Supplementary Fig. 4), a finding of note, given the presence 
of hamartomatous polyps in the intestines of some individuals with 
Cowden syndrome who carry germline PTEN mutations13. There was 
a small increase in the levels of cytoplasmic phosphorylated Akt in 
polyps from subjects with HMPS (Supplementary Fig. 4), although 
this was not spatially identical to the changes in PTEN expression.
In summary, we have shown that the Mendelian colorectal poly-
posis syndrome HMPS results from a duplication of approximately 
40 kb upstream of the gene that encodes the secreted BMP antagonist 
GREM1. Although the duplication includes some sequence within the 
neighboring SCG5 gene, no difference in SCG5 expression was found 
relative to controls. Whereas the duplication predisposes to benign 
lesions that are hypothesized to progress to CRCs in some cases, some 
sporadic adenomas and CRCs acquire low-level ectopic epithelial 
expression of GREM1 (S.L., H.D., P.R.C., A.L. and I.T., unpublished 
data), suggesting that the increased levels of GREM1 in HMPS may 
act to promote multiple stages of colorectal tumorigenesis. To date, 
we have only found the HMPS duplication in the Ashkenazi Jewish 
descendants of a single founder, but we do not exclude the possibility 
that rare affected individuals of other ancestry might carry pathogenic 
copy-number changes or other mutations in GREM1 that modestly or 
considerably increase the risk of CRC. In this regard, it is noteworthy 
that a single CRC case with whole-gene duplication of GREM1 has 
been reported14, although, if pathogenic rather than incidental, this 
mutation produces features of hereditary non-syndromic CRC15 
rather than HMPS. It is also notable that our genome-wide association 
studies have shown that common SNPs (rs16969681 and rs11632715) 
within the HMPS duplication are associated with relatively modest 
differences in CRC risk in the general population11. We suggest that 
the HMPS duplication is causally associated with increased ectopic 
GREM1 transcription in colorectal epithelium. Deletion of a limb 
bud–specific Grem1 control region within Fmn1 is known to lead to 
a limb deformity phenotype in mice16; we wonder whether the HMPS 
duplication involves an intestine-specific GREM1 control region that 
lies partly within SCG5. Although no reliable antibody to GREM1 
exists, it is expected that increased mRNA causes increased secre-
tion of epithelial GREM1 protein and, hence, a reduction in BMP 
signaling to the crypt cells. A reduction in BMP signaling is also 
the likely cause of JPS, in which either the type 1A BMP receptor 
BMPR1A or the downstream BMP effector SMAD4 is mutated and 
functionally defective17,18. The detailed functional consequences of 
the HMPS duplication, including full mapping of regulatory sites and 
the downstream effects of inactivating BMP signaling, await further 
investigation in the context of HMPS, but plausible modes of action 
include aberrant stem cell numbers or function and effects on the 
non-canonical BMP pathway via PTEN. It seems highly unlikely that 
all the cells overexpressing GREM1 in the normal bowel of individuals 
with HMPS represent early tumor clones. One potential pathogenic 
mechanism underlying HMPS is an increase in the number of cells 
that are susceptible to tumor-causing mutations, probably through 
microenvironmental effects of increased GREM1 secretion.
URLs. Integrated Regulation from ENCODE Tracks, http://genome.
ucsc.edu/cgi-bin/hgTrackUi?hgsid=219213609&c=chr15&g= 
wgEncodeReg; Oxford Gene Technology aCGH, http://www.ogt.co.uk/ 
gs-arrayCGH.asp.
MeTHodS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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Subjects and samples. Individuals and families were originally classified as 
possibly having a diagnosis of HMPS on the basis of the presence of multiple 
early-onset colorectal polyps (including some of serrated or mixed morphol-
ogy) coupled with no obvious excess of the extra-colonic tumors typical of 
other Mendelian CRC syndromes. Samples having germline mutations in APC, 
MUYTH, MSH2, MLH1, MSH6, PMS2, STK11 (also known as LKB1), SMAD4 
and BMPR1A were excluded. After identification of the Ashkenazi HMPS 
haplotype, the presence of this haplotype was used to confirm diagnosis, with 
this testing indicating that all Ashkenazi families with HMPS showed evidence 
of dominant inheritance of the disease. Any non-Jewish affected individuals 
(or Jewish affected individuals without the HMPS haplotype) with features 
suggestive of HMPS were classified as possibly having HMPS, although very 
few of these had evidence of dominantly inherited disease, and many were 
given a presumptive primary diagnosis of hyperplastic polyposis syndrome6.
Ethical approval for the study was provided by the Southampton and South-
West Hampshire Research Ethics Committee A. After obtaining informed 
consent, peripheral blood samples were taken, and DNA was extracted from 
these subjects. Tumor samples, including CRCs, were obtained from histo-
pathology archives. Fresh biopsies of normal bowel were additionally taken 
from a number of individuals with HMPS at colonoscopy and from tumor-
free individuals who were having investigative colonoscopy for symptoms 
subsequently shown to have innocent origins.
Lymphoblastoid cell lines were derived from several subjects with HMPS 
and unaffected family members and from one affected individual; two somatic 
cell hybrids were derived in a mouse NIH-3T3 background, with each hybrid 
containing a single copy of chromosome 15 carrying the mutant or wild-type 
haplotype at the HMPS locus.
Genotyping and variant screening. Microsatellite genotyping employed 
fluorescence-based fragment analysis on ABI3730 sequencers.
Copy-number analysis was undertaken using an Oxford Gene Technology 
(OGT) custom-designed oligonucleotide microarray comprising 6,761 probes 
spanning a 2.2-Mb region that was delimited on the basis of critical flanking 
recombinants from linkage analysis data available at the time. In brief, test 
DNA (from subjects with HMPS or unaffected family member) was labeled 
with Cy5, and control DNA (a standard reference) was labeled with Cy3. DNA 
was simultaneously hybridized to the arrays, and the ratios of Cy3/Cy5 intensi-
ties were measured. Copy-number gain was assessed as a consistent relative 
increase in Cy5, and copy-number loss was assessed as an increase in Cy3, 
using proprietary OGT software.
Illumina Infinium Hap550 arrays were used for SNP genotyping and sub-
sequently for copy-number analysis. HMPS samples were analyzed alongside 
a larger sample set from the CORGI genome-wide association study of CRC 
susceptibility in the general UK population. Quality control analysis was per-
formed as described for the CORGI study11. Copy-number analysis on data 
from the Hap550 arrays was performed using the QuantiSNP program7.
DNA sequencing was originally performed using conventional Sanger 
sequencing on the ABI3730 sequencer, and analysis was performed by vis-
ual inspection of sequence electropherograms from the mutant and wild-
type somatic cell hybrids, on the basis of human-specific amplicons. More 
recently, sequencing was performed using the Roche454 GSFlex system and 
software. The region of interest was tiled with long-range PCR amplimers, 
and amplification products were pooled at equal stoichiometric concentra-
tions. Sequencing libraries were prepared using the Roche 454 Rapid Library 
preparation method, and each sample was tagged with a unique molecular 
identifier before pooling and emulsion PCR amplification. In total, 200 Mb 
of sequencing data were generated, which was demultiplexed and analyzed 
using Roche gsMapper software.
Information on all PCR primer sequences and reaction conditions are avail-
able on request. Human Genome Build36 was used as a reference throughout 
this manuscript.
Quantitative RT-PCR. The TaqMan system was used to analyze the expression 
of GREM1, SCG5, FMN1 and LGR5. Small biopsies of normal bowel were taken 
from the ileum and throughout the colorectum of HMPS cases and controls. 
Tissue was incubated in 5 ml of DMEM (Invitrogen) supplemented with 30 mM 
EDTA (Sigma), 0.1 M dithiothreitol and 100 µl of RNAlater (Ambion) for 
15 min. Tissue was transferred to PBS and then vigorously shaken for 20 s. 
Individual intestinal crypts were drawn up using glass pipettes and transferred 
to RNA lysis buffer (Qiagen). After several cycles of shaking with fresh PBS 
washes, complete epithelial denudement occurred, and the residual mesen-
chymal tissue was collected and processed. Extracted mRNA was analyzed by 
qRT-PCR on the ABI7700 system. Primers and probes for test mRNA (details 
on request) were obtained from the ABI catalog. A GAPDH control probe was 
used. Expression levels were determined using the standard ∆∆CT method.
Allele-specific expression (ASE). ASE analysis was performed following a pre-
viously described protocol19. A TaqMan SNP genotyping assay for rs12915554 
within the 3′ UTR of the GREM1 gene was used to identify two subjects with 
HMPS and three control subjects that were heterozygotes. Phase was assigned 
using existing genotyping data, including those from the somatic cell hybrids. 
DNA from control homozygote was mixed in different ratios, and fluorescent 
intensity data were used to generate a linear regression standard curve. ASE 
for the heterozygotes with HMPS and control cDNA from individual crypts 
were then measured using qRT-PCR, and the gene expression allelic ratio 
was measured by intercepting the log of the fluorescent intensity ratio on the 
standard curve.
In situ tissue analyses. Sections (4 µm) were dewaxed and rehydrated by stand-
ard methods. Endogenous peroxidase activity was blocked with 3% H2O2 in 
methanol for 10 min. Antigen retrieval was achieved by 10 min of pressure cook-
ing in sodium citrate buffer at pH 6. Slides were blocked in goat serum for 30 min. 
The following primary antibodies were used for immunohistochemistry: 
rabbit antibody to phosphorylated SMAD1/5/8, which recognizes the phos-
phorylated forms of SMAD1 (Ser463/465), SMAD 5 (Ser463/465) and SMAD8 
(Ser426/428) (1:50 dilution; Cell Signaling Technology, 9511), rabbit antibody 
to PTEN (1:100 dilution; Cell Signaling Technology, 9188) and rabbit antibody 
to Akt phosphorylated at Ser473 (1:50 dilution; Cell Signaling Technology, 
4060). Then, samples were incubated with a 1:200 dilution of biotinylated poly-
clonal goat antibody recognizing rabbit (DAKO, E0432) before incubation in 
ABC (containing avidin and biotinylated horseradish peroxidase) (Vector 
Labs). Each antibody was applied for 30 min, and three 5-min PBS washes 
were performed. Sections were then developed with 3,3-diaminobenzidine- 
tetrahydrochloride solution (DAB; Sigma) for 2 min, rinsed in tap water and 
stained with light hematoxylin counterstain. Negative controls underwent the same 
steps but were incubated with PBS instead of the primary antibody solution.
Because suitable antibodies continue to be unavailable, expression levels 
of GREM1, FMN1 and LGR5 were analyzed by mRNA ISH using a previ-
ously described method20 with [35S]-labeled riboprobes. SCG5 was prima-
rily analyzed in this way, although immunohistochemistry was also used to 
provide supporting evidence. Details of the riboprobes used are available on 
request. Expression was scored in a qualitative fashion as present or absent or 
as stronger or weaker than in control samples analyzed alongside the samples 
from individuals with HMPS.
Assessment of the control of GREM1 expression. For luciferase reporter 
assays, the region chr. 15: 30,778,456–30,782,505 was cloned into the pGL3-
Promoter vector (Promega) in forward and reverse orientations to test 
enhancer function. SW948 cells were transiently co-transfected (in triplicate) 
with the appropriate pGL3-Promoter constructs and the Renilla luciferase 
pGL4.75 vector (Promega), as a control for transfection efficiency. After 
48 h, luciferase activity was measured (Dual-Glo Luciferase Assay System, 
Promega), and firefly luciferase activity from enhancer regions was normal-
ized to Renilla luciferase values for each sample. Background levels of firefly 
luciferase activity were assayed by transfecting cells with a control plasmid 
consisting of a noncoding 2.2-kb stretch of plasmid sequence (taken from the 
pENTR1A plasmid, Invitrogen) cloned into the pGL3-Promoter vector. These 
values were further used to normalize test luciferase measurements.
3C was performed following a previously described protocol21. 
Approximately 1 × 107 cells (at 90–100% confluence) were cross-linked with 
1% formaldehyde for 20 min and quenched with 125 mM glycine. After shaking 
the cells for more than 30 min in lysis buffer (50 mM Tris, pH 7.5, 150 mM 



























nuclei were pelleted (300g for 5 min) and resuspended in 360 µl of H2O and 
60 µl of the 10× restriction buffer for BglII. After 1 h of incubation in 3.75% 
SDS and subsequent quenching with 37.5% Triton X-100, 400–800 U of BglII 
was added, and samples were incubated overnight at 37 °C. The ligation 
reaction used a 10× higher volume to favor ligation events between cross-
linked DNA strands with 50 U of T4 Ligase (Roche, 5 U/µl), and reactions 
were incubated at 16 °C over 1–2 nights. To reverse cross-linking, 30 µl of 
Proteinase K (10 mg/ml) was added, and reactions were incubated overnight 
at 65 °C. After phenol extraction and ethanol precipitation, the samples were 
recovered in 500 µl of TrisEDTA buffer (Sigma). Elute (4 µl) was used for 
qRT-PCR in the TaqMan Fast Universal PCR System (Applied Biosystems). 
Data were normalized to cross-linking frequencies for the RP11-420B6 BAC. 
The ratio of the test data points to the adjacent upstream primer data was used 
to compare results between cell lines.
19. Lo, H.S. et al. Allelic variation in gene expression is common in the human genome. 
Genome Res. 13, 1855–1862 (2003).
20. Poulsom, R., Longcroft, J.M., Jeffery, R.E., Rogers, L.A. & Steel, J.H. A robust 
method for isotopic riboprobe in situ hybridisation to localise mRNAs in routine 
pathology specimens. Eur. J. Histochem. 42, 121–132 (1998).
21. Miele, A., Gheldof, N., Tabuchi, T.M., Dostie, J. & Dekker, J. Mapping chromatin 
interactions by chromosome conformation capture. Curr. Protoc. Mol. Biol.  
Chapter 21, Unit 21.11 (2006).
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